Veracyte Reports Strong Q4 2025 Earnings with 19% Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VCYT?
Source: seekingalpha
- Significant Revenue Growth: Veracyte reported $141 million in revenue for Q4 2025, marking a 19% year-over-year increase, primarily driven by robust performance in its core testing business, which underscores the durability of its growth model and future opportunities.
- Testing Volume Increase: The volumes for Decipher and Afirma grew by 21% and 12%, respectively, leading to a total testing volume growth of 16%, providing clinically actionable information to nearly 170,000 patients, with plans to test the one millionth patient later this year, further solidifying market position.
- EBITDA Margin Exceeds Expectations: The adjusted EBITDA margin surpassed 27%, exceeding the 25% target more than a year ahead of schedule, reflecting the company's success in operational efficiency and cost control, which enhances flexibility for future investments.
- Positive 2026 Outlook: The company anticipates total revenue guidance for 2026 to be between $570 million and $582 million, representing a 10% to 13% year-over-year growth, with plans to launch new products TrueMRD and Prosigna, further driving revenue growth and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCYT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCYT
Wall Street analysts forecast VCYT stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 35.690
Low
43.00
Averages
46.25
High
50.00
Current: 35.690
Low
43.00
Averages
46.25
High
50.00
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veracyte Reports Strong Q4 2025 Earnings with 19% Revenue Growth
- Significant Revenue Growth: Veracyte reported $141 million in revenue for Q4 2025, marking a 19% year-over-year increase, primarily driven by robust performance in its core testing business, which underscores the durability of its growth model and future opportunities.
- Testing Volume Increase: The volumes for Decipher and Afirma grew by 21% and 12%, respectively, leading to a total testing volume growth of 16%, providing clinically actionable information to nearly 170,000 patients, with plans to test the one millionth patient later this year, further solidifying market position.
- EBITDA Margin Exceeds Expectations: The adjusted EBITDA margin surpassed 27%, exceeding the 25% target more than a year ahead of schedule, reflecting the company's success in operational efficiency and cost control, which enhances flexibility for future investments.
- Positive 2026 Outlook: The company anticipates total revenue guidance for 2026 to be between $570 million and $582 million, representing a 10% to 13% year-over-year growth, with plans to launch new products TrueMRD and Prosigna, further driving revenue growth and market expansion.
See More
Veracyte Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Performance: Veracyte's Q4 non-GAAP EPS of $0.53 surpassed expectations by $0.12, indicating a sustained enhancement in profitability that reinforces investor confidence in future growth prospects.
- Significant Revenue Growth: The company reported Q4 revenue of $140.6 million, an 18.5% year-over-year increase, exceeding expectations by $4.81 million, which reflects its competitive position and rising product demand in the market, driving overall performance improvement.
- Clear Future Guidance: Veracyte reiterated its total revenue guidance for 2026 at $570 million to $582 million, with a growth rate of 10% to 13%, indicating strong confidence in future business development, particularly in testing revenue projected to grow by 14% to 16%.
- Testing Revenue Drivers: Excluding contributions from new tests, the company anticipates testing revenue to reach $560 million to $570 million, showcasing robust performance in its core business and sustained market demand, further strengthening its market position.
See More
Veracyte to Participate in Investor Conferences
- Conference Participation: Veracyte will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL, on March 3rd at 8:05 a.m. Eastern Time, showcasing its latest advancements in cancer diagnostics.
- Health Conference: Additionally, Veracyte will engage in a fireside chat at the Leerink Partners Global Health Conference in Miami, FL, on March 9th at 10:40 a.m. Eastern Time, further enhancing its interaction with investors.
- Live Webcasts: The company will provide live audio webcasts of its presentations via its official website, allowing investors to access real-time information by visiting http://investor.veracyte.com/events-presentations, ensuring transparency and accessibility.
- Replay Availability: Following each live presentation, Veracyte will offer a 90-day replay service, enabling investors who cannot attend live to access the information, thereby strengthening communication and trust between the company and its investors.
See More
Veracyte to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Veracyte will announce its fourth quarter and full-year 2025 financial results after market close on February 25, 2026, reflecting the company's ongoing advancements in cancer diagnostics.
- Conference Call Details: Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss financial results and provide a business update, enhancing investor confidence in the company's future.
- Webcast Availability: The conference call will be streamed live on the company's website, with a replay available post-broadcast, ensuring that investors who cannot attend live can access critical information.
- Company Vision: Veracyte aims to transform cancer care through its high-performing diagnostics platform, leveraging extensive genomic and clinical data to solidify its leadership position in the global cancer diagnostics market.
See More
Veracyte Inc Shares Enter Oversold Territory
- Oversold Signal: Veracyte Inc (Ticker: VCYT) hit an RSI of 29.0 on Wednesday, indicating an oversold condition, suggesting that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Price Fluctuation: VCYT shares traded as low as $35.72, with the current price at $36.10, showing significant volatility compared to the 52-week low of $22.61 and high of $50.71, reflecting drastic market sentiment changes.
- Market Comparison: The low RSI of VCYT, compared to the S&P 500 ETF (SPY) RSI of 52.7, may attract bullish investors, indicating potential rebound opportunities that could influence future buying decisions.
- Investor Sentiment: Despite the current poor stock performance, the oversold signal may lead investors to reassess their strategies, especially amid increasing market volatility, potentially resulting in capital inflows.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
Veracyte Reports Strong Q4 2025 Earnings with 19% Revenue Growth
- Significant Revenue Growth: Veracyte reported $141 million in revenue for Q4 2025, marking a 19% year-over-year increase, primarily driven by robust performance in its core testing business, which underscores the durability of its growth model and future opportunities.
- Testing Volume Increase: The volumes for Decipher and Afirma grew by 21% and 12%, respectively, leading to a total testing volume growth of 16%, providing clinically actionable information to nearly 170,000 patients, with plans to test the one millionth patient later this year, further solidifying market position.
- EBITDA Margin Exceeds Expectations: The adjusted EBITDA margin surpassed 27%, exceeding the 25% target more than a year ahead of schedule, reflecting the company's success in operational efficiency and cost control, which enhances flexibility for future investments.
- Positive 2026 Outlook: The company anticipates total revenue guidance for 2026 to be between $570 million and $582 million, representing a 10% to 13% year-over-year growth, with plans to launch new products TrueMRD and Prosigna, further driving revenue growth and market expansion.
See More
Veracyte Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Performance: Veracyte's Q4 non-GAAP EPS of $0.53 surpassed expectations by $0.12, indicating a sustained enhancement in profitability that reinforces investor confidence in future growth prospects.
- Significant Revenue Growth: The company reported Q4 revenue of $140.6 million, an 18.5% year-over-year increase, exceeding expectations by $4.81 million, which reflects its competitive position and rising product demand in the market, driving overall performance improvement.
- Clear Future Guidance: Veracyte reiterated its total revenue guidance for 2026 at $570 million to $582 million, with a growth rate of 10% to 13%, indicating strong confidence in future business development, particularly in testing revenue projected to grow by 14% to 16%.
- Testing Revenue Drivers: Excluding contributions from new tests, the company anticipates testing revenue to reach $560 million to $570 million, showcasing robust performance in its core business and sustained market demand, further strengthening its market position.
See More
Veracyte to Participate in Investor Conferences
- Conference Participation: Veracyte will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL, on March 3rd at 8:05 a.m. Eastern Time, showcasing its latest advancements in cancer diagnostics.
- Health Conference: Additionally, Veracyte will engage in a fireside chat at the Leerink Partners Global Health Conference in Miami, FL, on March 9th at 10:40 a.m. Eastern Time, further enhancing its interaction with investors.
- Live Webcasts: The company will provide live audio webcasts of its presentations via its official website, allowing investors to access real-time information by visiting http://investor.veracyte.com/events-presentations, ensuring transparency and accessibility.
- Replay Availability: Following each live presentation, Veracyte will offer a 90-day replay service, enabling investors who cannot attend live to access the information, thereby strengthening communication and trust between the company and its investors.
See More
Veracyte to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Veracyte will announce its fourth quarter and full-year 2025 financial results after market close on February 25, 2026, reflecting the company's ongoing advancements in cancer diagnostics.
- Conference Call Details: Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss financial results and provide a business update, enhancing investor confidence in the company's future.
- Webcast Availability: The conference call will be streamed live on the company's website, with a replay available post-broadcast, ensuring that investors who cannot attend live can access critical information.
- Company Vision: Veracyte aims to transform cancer care through its high-performing diagnostics platform, leveraging extensive genomic and clinical data to solidify its leadership position in the global cancer diagnostics market.
See More
Veracyte Inc Shares Enter Oversold Territory
- Oversold Signal: Veracyte Inc (Ticker: VCYT) hit an RSI of 29.0 on Wednesday, indicating an oversold condition, suggesting that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Price Fluctuation: VCYT shares traded as low as $35.72, with the current price at $36.10, showing significant volatility compared to the 52-week low of $22.61 and high of $50.71, reflecting drastic market sentiment changes.
- Market Comparison: The low RSI of VCYT, compared to the S&P 500 ETF (SPY) RSI of 52.7, may attract bullish investors, indicating potential rebound opportunities that could influence future buying decisions.
- Investor Sentiment: Despite the current poor stock performance, the oversold signal may lead investors to reassess their strategies, especially amid increasing market volatility, potentially resulting in capital inflows.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
